Interpace Q2 Revenue Dips 1% but Thyroid Business Grows 9%, Margins Expand
IDXG has more than doubled off its 52-week low of $0.76 on elevated volume (2.9× avg).
Summary
Interpace Biosciences reported Q2 revenue of $9.13M, down 1% year-over-year, but its core thyroid business grew 9% with a 6% increase in test volume. The company swung to a net income of $158K from a prior-year loss, driven by gross margin expansion to $5.65M and operating income of $321K. This follows a Q1 that saw a 22% revenue decline after discontinuing the PancraGEN test, making the thyroid-only focus a critical pivot. Management expects continued margin improvement through 2026 and does not anticipate pancreatic cancer program revenue this year. The results show early traction in the streamlined business model, though overall revenue remains under pressure.
At the time of this announcement, IDXG was trading at $1.70 on OTC in the Life Sciences sector, with a market capitalization of approximately $47.1M. The 52-week trading range was $0.76 to $2.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.